Xenetic Biosciences (XBIO) Total Current Liabilities (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Total Current Liabilities came in at $958239.0 in Q1 2026, up 43.46% YoY from $667927.0 in Q1 2025, and down 1.01% on a QoQ basis from $968025.0 in Q4 2025.
Xenetic Biosciences (XBIO) Total Current Liabilities (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Total Current Liabilities data on file, last reported at $958239.0 in Q1 2026.
- Quarterly Total Current Liabilities rose 43.46% year-over-year to $958239.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $958239.0 (up 43.46% YoY) and the FY2025 annual result came in at $968025.0, up 8.25% from the prior year.
- Total Current Liabilities retreated to $958239.0 in Q1 2026, from $968025.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.6 million in Q2 2024 to a low of $667927.0 in Q1 2025.
- A 5-year average of $993493.5 and a median of $968025.0 in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 82.21% — and 2025, when it sank 43.09%.
- Tracing XBIO's Total Current Liabilities over 5 years: stood at $1.1 million in 2022, then retreated by 24.56% to $809585.0 in 2023, then increased by 10.46% to $894263.0 in 2024, then climbed by 8.25% to $968025.0 in 2025, then decreased by 1.01% to $958239.0 in 2026.
- The last three Total Current Liabilities figures came in at $958239.0 (Q1 2026), $968025.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 630.93 Mn |
| 10 | Xenetic Biosciences | 7.71 Mn | 1.24 Mn | - | 894,977.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 894,977.00 |
| Mar 31, 2026 | 958,239.00 |
| Dec 31, 2025 | 968,025.00 |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 903,430.00 |
| Mar 31, 2025 | 667,927.00 |
| Dec 31, 2024 | 894,263.00 |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 716,494.00 |
| Dec 31, 2023 | 809,585.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 871,315.00 |
| Mar 31, 2023 | 856,365.00 |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.12 Mn |